FIGURE 5
FROM:
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo
M Wang, X H Han, L Zhang, J Yang, J F Qian, Y K Shi, L W Kwak, J Romaguera and Q Yi
BACK TO ARTICLEFigure 5.
In vivo therapeutic effects of BTZ, CTX, RTX, RC and BRC on established MCL in SCID mouse model. (a) Tumor volumes and (b) survival of tumor-bearing SCID mice. CB-17 SCID mice were inoculated subcutaneously in the right flank with 8 
106 Jeko-1 cells. Four weeks later, when palpable tumors (
5 mm in diameter) developed, mice (10 per group) were treated with intraperitoneal injections of BTZ (1.0 mg kg-1 day-1), RTX (10 mg kg-1 day-1) or CTX (40 mg kg-1 day-1) on days 1, 4, 7 and 10. RC and BRC regimen-treated cohorts received the drugs at the same concentrations on the same time points. Mice receiving injection of PBS on the same day were used as controls.